stoxline Quote Chart Rank Option Currency Glossary
  
Aprea Therapeutics, Inc. (APRE)
5.73  0.03 (0.53%)    04-17 16:00
Open: 5.71
High: 5.8484
Volume: 2,277
  
Pre. Close: 5.7
Low: 5.71
Market Cap: 31(M)
Technical analysis
2024-04-17 4:44:59 PM
Short term     
Mid term     
Targets 6-month :  7.21 1-year :  8.03
Resists First :  6.18 Second :  6.88
Pivot price 6.15
Supports First :  5.05 Second :  4.2
MAs MA(5) :  5.81 MA(20) :  6.16
MA(100) :  5.57 MA(250) :  4.5
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  34.2 D(3) :  34.3
RSI RSI(14): 42.3
52-week High :  8.84 Low :  2.77
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ APRE ] has closed above bottom band by 15.4%. Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.86 - 5.89 5.89 - 5.93
Low: 5.62 - 5.65 5.65 - 5.69
Close: 5.66 - 5.72 5.72 - 5.79
Company Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Headline News

Wed, 17 Apr 2024
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World

Wed, 03 Apr 2024
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia ... - AOL

Sat, 30 Mar 2024
Aprea Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.80) Per Share, HC Wainwright Forecasts (NASDAQ:APRE) - Defense World

Tue, 26 Mar 2024
APRE Stock Quote Price and Forecast - CNN

Thu, 14 Mar 2024
Aprea Therapeutics CFO buys $7,362 in company stock By Investing.com - Investing.com

Wed, 13 Mar 2024
Aprea Therapeutics Secures Funding and Advances Drug Pipeline - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 5 (M)
Held by Insiders 4.19e+006 (%)
Held by Institutions 11.6 (%)
Shares Short 70 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.546e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -26 %
Return on Assets (ttm) 109.6 %
Return on Equity (ttm) -36.7 %
Qtrly Rev. Growth 583230 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 105830
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android